Genprex discussed moving beyond oncology into diabetes with a one-time gene therapy approach, positioning a platform strategy intended to deliver durable metabolic impact. The multi-part series reflects how companies are reusing gene therapy capabilities across disease areas with unmet long-term treatment needs. The diabetes pivot matters because it highlights the competitive landscape for one-time interventions, where efficacy durability, safety, and manufacturing feasibility determine whether gene therapy becomes a mainstream category outside rare diseases. For investors and partners, the most immediate watchpoints are whether preclinical rationale translates to clinical durability and how development timelines manage the added complexity of metabolic endpoints.